Zai Lab
Zai Lab is a US-China biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative oncology, immunology, neuroscience, and infectious disease therapies for patients across Greater China and select global markets, with eight approved products and six on China's National Reimbursement Drug List.
- Company typePublic
- Founded2014
- HeadquartersShanghai, China
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Zai Lab does
Zai Lab Limited is an innovation-driven, commercial-stage biopharmaceutical company founded in 2014 and dual-listed on NASDAQ (ZLAB) and the Hong Kong Stock Exchange (09688.HK), with operational headquarters in Shanghai and Cambridge, Massachusetts. The company discovers, develops, manufactures, and commercializes innovative therapeutics for oncology, immunology, neuroscience, and infectious disease, serving patients and healthcare providers across Greater China with a growing global footprint in the US, Europe, and Asia Pacific.
Zai Lab operates an end-to-end model spanning internal discovery through commercial manufacturing, anchored by a proprietary pipeline that includes the lead DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan (zoci), the IL-13/IL-31R bispecific ZL-1503, the LRRC15 ADC ZL-6201, and the PD-1/IL-12 immunocytokine ZL-1222. Eight products are approved in mainland China, including ZEJULA, OPTUNE GIO, QINLOCK, AUGTYRO, TIVDAK, VYVGART, NUZYRA, XACDURO, and COBENFY, with six on the National Reimbursement Drug List. Manufacturing capabilities include small-molecule facilities in Suzhou (20M hard capsules and 50M tablets annually) and a 4,200 sqm large-molecule facility with GE Flexfactory.
The business model combines in-licensed product commercialization in Greater China with proprietary global pipeline development, generating revenue through product sales supplemented by licensing and partnership arrangements with partners including argenx, Karuna/BMS, Seagen/Pfizer, Vertex, Blueprint Medicines, GSK, Regeneron, BMS, and Novocure. Distribution relies on a specialized disease-franchise commercial organization covering mainland China, Hong Kong, Macau, and Taiwan, with NRDL inclusion, patient assistance programs, and Named Patient Programs driving access. In FY2025, Zai Lab generated $460.2M in revenue (15% YoY growth) with a $175.5M net loss, supported by a $761.3M cash position as of Q1 2026 and approximately 2,100 employees globally.
Zai Lab firmographics
Firmographics- Name
- Zai Lab
- Legal name
- Zai Lab Limited
- Website
- https://zailaboratory.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Zai Lab is a US-China biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative oncology, immunology, neuroscience, and infectious disease therapies for patients across Greater China and select global markets, with eight approved products and six on China's National Reimbursement Drug List.
- Ownership category
- akta.pro rank
Where Zai Lab is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices8 records
Markets served
Zai Lab business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Product Sales - Oncology: Sales of approved oncology products including ZEJULA (niraparib), OPTUNE GIO, QINLOCK (ripretinib), AUGTYRO (repotrectinib), and TIVDAK (tisotumab vedotin). Zai Lab currently has eight approved products in mainland China.
- Product Sales - Immunology: Sales of efgartigimod (VYVGART) for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP).
- Product Sales - Infectious Disease: Sales of NUZYRA (omadacycline) for CABP and ABSSSI, and XACDURO (sulbactam-durlobactam) for HABP/VABP.
- Product Sales - Neuroscience: Sales of COBENFY (xanomeline and trospium chloride) for schizophrenia following December 2025 NMPA approval.
- Licensing and Partnership Revenue: Revenue from licensing agreements with partners including Karuna Therapeutics for COBENFY in Greater China, Seagen/Pfizer for TIVDAK, and collaborations with global pharmaceutical companies.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Zai Lab product offering
Product offeringCore offering
Zai Lab is a commercial-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative therapeutics for oncology, immunology, neuroscience, and infectious diseases, with eight approved products currently marketed in mainland China and a global pipeline of proprietary candidates. The company combines in-licensed assets from partners such as argenx, Pfizer/Seagen, Karuna/BMS, and Novocure with internally developed antibody-drug conjugates and bispecifics to serve patients and healthcare providers primarily across Greater China, with growing global commercialization plans for the US, Europe, and Asia Pacific.
Differentiator
Problem solved
Functional benefit
Products and services
- ZEJULA (niraparib) PARP inhibitor for first-line maintenance treatment and recurrent maintenance therapy of ovarian cancer, marketed in Greater China.
- OPTUNE GIO (Tumor Treating Fields) Tumor Treating Fields delivery system for the treatment of newly diagnosed and recurrent glioblastoma, marketed in Greater China in partnership with Novocure.
- QINLOCK (ripretinib) Tyrosine kinase inhibitor for fourth-line treatment of advanced gastrointestinal stromal tumors (GIST), marketed in mainland China.
- AUGTYRO (repotrectinib) Tyrosine kinase inhibitor for the treatment of ROS1-positive non-small cell lung cancer (NSCLC) and NTRK-positive solid tumors, marketed in Greater China.
- TIVDAK (tisotumab vedotin) Antibody-drug conjugate (tisotumab vedotin) for adult patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy, marketed in Greater China under license from Seagen/Pfizer.
- VYVGART (efgartigimod) FcRn antagonist (efgartigimod alfa) for adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), marketed in Greater China under partnership with argenx.
- NUZYRA (omadacycline) Broad-spectrum antibiotic (omadacycline) for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), marketed in mainland China.
- XACDURO (sulbactam-durlobactam) Antibiotic combination (sulbactam-durlobactam) for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex, marketed in China.
- COBENFY (xanomeline and trospium chloride) M1/M4 muscarinic receptor agonist combination (xanomeline and trospium chloride) for the treatment of schizophrenia in adults, marketed in Greater China under license from Karuna Therapeutics (Bristol-Myers Squibb).
Quantifiable outcome
- 45% reduction in risk of death (HR: 0.55) in China subpopulation for TIVDAK vs chemotherapy in recurrent/metastatic cervical cancer
- +4 more outcomes
Companies that use Zai Lab
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Zai Lab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Zai Lab partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Boehringer IngelheimcoreCollaboration on DLL3-targeting T-cell engager and ADC combination in small cell lung cancer and other neuroendocrine carcinomas. The collaboration combines Zai Lab's zoci ADC with Boehringer Ingelheim's DLL3-targeting bispecific T-cell engager therapy.
- AmgencoreGlobal clinical trial collaboration to evaluate Zai Lab's zocilurtatug pelitecan (DLL3-targeting ADC) in combination with Amgen's IMDELLTRA for extensive-stage small cell lung cancer. Amgen sponsors and leads the Phase 1b study while Zai Lab retains full ownership of its ADC and provides clinical supply.
- VertexcoreCollaboration on povetacicept (BAFF/APRIL) in IgA nephropathy. Zai Lab has exclusive license to develop and commercialize povetacicept in mainland China, Hong Kong, Macau, Taiwan, and Singapore.
Scale indicators10 records
Recent moves13 records
Expansion highlights6 records
Zai Lab competitors and assessment
Company assessmentDirect peers
- BeiGene (now BeOne Medicines): China-founded, US-listed biopharmaceutical company with a similar business model combining a profitable China commercial organization (BRUKINSA, etc.) with a global innovation pipeline. Direct peer in oncology-focused biopharma bridging China and global markets.
- HUTCHMED (China) Limited: China-founded, Hong Kong and NASDAQ-listed biopharma developing and commercializing oncology and immunology therapies in China and globally. Comparable in China-focused oncology R&D and commercialization, with overlapping NRDL-listed products and global out-licensing strategy.
- Innovent Biologics: China-based biopharma with multiple approved and NRDL-included products in oncology (TYVYT/PD-1, etc.) and growing pipeline. Closely comparable in China commercialization scale, NRDL positioning, and dual China-US R&D footprint.
- Akeso, Inc. China-based biopharma developing novel antibodies including PD-1/VEGF bispecifics, with growing commercialization in oncology and immunology. Comparable in novel biologics discovery, China NRDL access, and dual China/global development strategy.
- Shanghai Junshi Biosciences: China-based biopharma with an approved PD-1 antibody (toripalimab) and broader oncology pipeline, dual-listed in Hong Kong and on STAR Market. Comparable as a China-headquartered immuno-oncology player with global ambitions.
Broad incumbents
- Hengrui Medicine: China's largest domestic pharmaceutical company with broad oncology, immunology, and other therapeutic portfolios plus extensive NRDL presence. Comparable as a China commercial-scale pharma competitor but with a much broader, established portfolio and generic + innovative mix.
- Hansoh Pharmaceutical Group: Large China-headquartered pharmaceutical company with multiple approved innovative drugs across oncology, CNS, and infectious disease. Comparable as a broad Chinese pharma operator with overlapping therapeutic categories and NRDL commercialization experience.
- CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharmaceutical conglomerate with oncology, neurology, and anti-infective product portfolios plus R&D pipeline. Comparable as a broad incumbent operating in Zai Lab's therapeutic categories and NRDL channels.
Others
- Bristol-Myers Squibb: Global biopharma and existing Zai Lab partner/seller of in-licensed products (QINLOCK, AUGTYRO, COBENFY via Karuna acquisition). Comparable as a global oncology and immunology player with overlapping therapeutic franchises and pipeline interest in DLL3 and related targets.
- Amgen: Global biopharma with the competing DLL3-targeted T-cell engager IMDELLTRA, and strategic clinical collaboration partner with Zai Lab on zoci + IMDELLTRA combinations. Comparable as a global oncology innovator with overlapping SCLC pipeline interests and partner-based China market access patterns.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Zai Lab social profiles
Digital presenceZai Lab financial estimates
Financial estimateRevenue estimate
Valuation estimate
Zai Lab leadership team
Management profileNumber of profiles
Profiles26 records
Zai Lab funding detail
Funding detailFunding overview
Funding rounds13 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Zai Lab M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Zai Lab
What does Zai Lab do?
Zai Lab is a commercial-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative therapeutics for oncology, immunology, neuroscience, and infectious diseases, with eight approved products currently marketed in mainland China and a global pipeline of proprietary candidates. The company combines in-licensed assets from partners such as argenx, Pfizer/Seagen, Karuna/BMS, and Novocure with internally developed antibody-drug conjugates and bispecifics to serve patients and healthcare providers primarily across Greater China, with growing global commercialization plans for the US, Europe, and Asia Pacific.
Is Zai Lab a public or private company?
Zai Lab is a public company. It is classified as public and is currently operating.
When was Zai Lab founded?
Zai Lab was founded in 2014. It employs 1,001 to 5,000 people.
Where is Zai Lab based?
Zai Lab is headquartered in Shanghai, China, in the Asia region.
How does Zai Lab make money?
Five revenue lines are on record. Product Sales - Oncology is the primary driver. The others are product Sales - Immunology, product Sales - Infectious Disease, product Sales - Neuroscience and licensing and Partnership Revenue.
Who are Zai Lab's main competitors?
Direct peers on record are BeiGene (now BeOne Medicines), HUTCHMED (China) Limited, Innovent Biologics, Akeso, Inc. and Shanghai Junshi Biosciences. Broad incumbents are Hengrui Medicine, Hansoh Pharmaceutical Group and CSPC Pharmaceutical Group. Others are Bristol-Myers Squibb and Amgen.
Does Zai Lab have an API?
No public API is recorded for Zai Lab.